81. Climatic regulation of leaf and cambial phenology in Quercus pubescens : their interlinkage and impact on xylem and phloem conduitsJožica Gričar, Jernej Jevšenak, Polona Hafner, Peter Prislan, Mitja Ferlan, Martina Lavrič, Dominik Vodnik, Klemen Eler, 2022, original scientific article Abstract: Increased frequency and severity of stressful events affects the growth patterns and functioning of trees which adjust their phenology to given conditions. Here, we analysed environmental effects (temperature, precipitation, VPD and SWC) on the timing of leaf phenology, seasonal stem radial growth patterns, and xylem and phloem anatomy of Quercus pubescens in the sub-Mediterranean in the period 2014%2019, when various adverse weather events occurred, i.e. spring drought in 2015, summer fire in 2016 and summer drought in 2017. Results showed that the timings of leaf and cambium phenology do not occur simultaneously in Q. pubescens, reflecting different environmental and internal constraints. Although year-to-year variability in the timings of leaf and cambial phenology exists, their chronological sequence is fairly fixed. Different effects of weather conditions on different stages of leaf development in spring were observed. Common climatic drivers (i.e., negative effect of hot and dry summers and a positive effect of increasing moisture availability in winter and summer) were found to affect the widths of xylem and phloem increments with more pronounced effect on late formed parts. A legacy effect of the timing of leaf and cambial phenology of the previous growing season on the timing of phenology of the following spring was confirmed. Rarely available phloem data permitted a comprehensive insight into the interlinkage of the timing of cambium and leaf phenology and adjustment strategies of vascular tissues in Mediterranean pubescent oak to various environmental constraints, including frequent extreme events (drought, fire). Our results suggest that predicted changes in autumn/winter and spring climatic conditions for this area could affect the timings of leaf and stem cambial phenology of Q. pubescens in the coming years, which would affect stem xylem and phloem structure and hydraulic properties, and ultimately its performance.
Keywords: pubescent oak, leaf development, radial growth, initial earlywood vessel, sieve tube, anatomy, cambial cell production, extreme weather events
Published in DiRROS: 06.09.2021; Views: 983; Downloads: 299
 Full text (7,00 MB)
This document has many files! More... |
82. Priporočila za zdravljenje bolnikov s ploščatoceličnim rakom kožeBarbara Perić, Olga Blatnik, Boštjan Luzar, Jože Pižem, Janja Ocvirk, Marko Hočevar, Primož Strojan, Tomi Bremec, Martina Reberšek, 2020, not set Keywords: ploščatocelični rak, rak (medicina), koža, bolniki, zdravljenje
Published in DiRROS: 07.04.2021; Views: 1330; Downloads: 420
Full text (191,24 KB) |
83. Gozd in gozdarstvo v SlovenijiKristina Sever, Martina Kastelec, Suzana Rankov, Miha Zupančič, Boštjan Hren, Andrej Breznikar, Marija Kolšek, Damjan Oražem, Boris Rantaša, Špela Planinšek, 2021, other educational material Keywords: gozdarstvo, gozdovi, Slovenija
Published in DiRROS: 22.03.2021; Views: 1296; Downloads: 524
Full text (6,80 MB) |
84. Rak debelega črevesa in danke : kaj morate vedeti o bolezniJanja Ocvirk, Vaneja Velenik, Franc Anderluh, Maja Ebert Moltara, Ibrahim Edhemović, Zvezdana Hlebanja, Irena Oblak, Martina Reberšek, 2013, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: rak debelega črevesa, rak danke, zdravljenje, bolniki, priročniki
Published in DiRROS: 19.03.2021; Views: 1111; Downloads: 386
Full text (2,31 MB) |
85. |
86. |
87. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapyMartina Vrankar, Matjaž Zwitter, Izidor Kern, Karmen Stanič, 2018, original scientific article Abstract: The standard treatment for inoperable locally advanced non-small cell lung cancer (LA NSCLC) includes concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Long term survival rates with these approaches remains only in the order of 15%, therefore new treatment strategies, including immunotherapy, are under investigation, with programmed death ligand-1 (PD-L1) as one of the major players. We evaluated the clinical significance of PD-L1 expression in tumor samples from patients with inoperable LA NSCLC who underwent concurrent chemoradiotherapy (CRT) in our institution between 2005 and 2010 and correlated their expression with clinicopathological parameters and outcome of treatment. Among 107 patients treated with concurrent CRT, a total of 43 (36 males and 7 females) had sufficient tissue for immunohistochemical (IHC) staining. The expression of PD-L1 was demonstrated in 7 tumors, in 6 males and 1 female. No statistical significant differences in patient characteristics, including age, smoking status and gender, were found according to the PD-L1 expression. After a median follow up of 103.6 months, median progression free survival (PFS) was 19.9 months in patients without and 10.1 months in patients with PD-L1 expression (p=0.008). Median overall survival (OS) was 28.4 and 12.1 months for PD-L1 negative and PD-L1 positive patients, respectively (p=0.012). In conclusions, patients with PD-L1 expression had shorter PFS and OS after concurrent CRT in LA NSCLC. Unfortunately, only small number of patients had tissue available for the IHC testing, therefore no firm conclusions could be made and further investigation is warranted.
Keywords: non-small cell lung cancer, lung cancer, chemoradiotherapy, survival
Published in DiRROS: 17.12.2020; Views: 1344; Downloads: 423
 Link to file |
88. |
89. |
90. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapyMartina Vrankar, Izidor Kern, Karmen Stanič, 2020, original scientific article Abstract: Background: Expression of PD-L1 is the most investigated predictor of benefit from immune checkpoint blockade in advanced NSCLC but little is known about the association of PD-L1 expression and clinicopathological parameters of patients with unresectable stage III NSCLC. Methods: National registry data was searched for medical records of consecutive inoperable stage III NSCLC patients treated with ChT and RT from January 2012 to December 2017. Totally 249 patients were identified that met inclusion criteria and of those 117 patients had sufficient tissue for PD-L1 immunohistochemical staining. Results: Eighty patients (68.4%) expressed PD-L1 of >- 1% and 29.9% of more than 50%. Median PFS was 15.9 months in PD-L1 negative patients and 16.1 months in patients with PD-L1 expression >- 1% (p = 0.696). Median OS in PD-L1 negative patients was 29.9 months compared to 28.5 months in patients with PD-L1 expression >- (p = 0.888). There was no difference in median OS in patients with high PD-L1 expression (>- 50%) with 29.8 months compared to 29.9 months in those with low (1-49%) or no PD-L1 expression (p = 0.694). We found that patients who received a total dose of 60 Gy or more had significantly better median OS (32 months vs. 17.5 months, p < 0.001) as well as patients with PS 0 (33.2 vs. 20.3 months, p = 0.005). Conclusions: In our patients PD-L1 expression had no prognostic value regarding PFS and OS. Patients with good performance status and those who received a total radiation dose of more than 60 Gy had significantly better mOS.
Keywords: non small cell lung cancer, chemoradiotherapy, stage III
Published in DiRROS: 09.11.2020; Views: 1424; Downloads: 1019
Full text (822,12 KB)
This document has many files! More... |
